Teva Pharmaceutical shares rise 2.18% premarket after Q2 profit beats estimates.

Wednesday, Jul 30, 2025 7:34 am ET1min read
Teva Pharmaceutical Industries Limited rose 2.18% in premarket trading. The company reported a Q2 profit that exceeded estimates, driven by gains in branded drugs. Additionally, Teva's innovative portfolio has fueled its 10th consecutive quarter of growth, indicating strong performance and potential for future success.

Teva Pharmaceutical shares rise 2.18% premarket after Q2 profit beats estimates.

Comments



Add a public comment...
No comments

No comments yet